Evidence map›Paper›PMID 40210447›Full record

ReviewCold Spring Harbor perspectives in biology2026

Biogenesis and Regulation of Telomerase during Development and Cancer.

Lu Chen, Luis Francisco Zirnberger Batista

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lu ChenCancer Signaling and Epigenetics Program and Cancer Epigenetics Institute, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA lu.chen@fccc.edu lbatista@wustl.edu.
Luis Francisco Zirnberger BatistaDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri 63110, USA lu.chen@fccc.edu lbatista@wustl.edu.

Funding

Telomerase RNP Prisonbreaks from Phase-Separated Nuclear BodyR35GM150538 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI Lu Chen · 2023 to 2026
$2.1M
Mechanisms and Relevance of miRNA Decay during Hematopoietic DevelopmentR01HL174789 · NHLBI · WASHINGTON UNIVERSITY · PI Luis Francisco Zirnberger Batista · 2024 to 2026
$1.9M
Telomere Dysfunction and Telomerase Reactivation in the Etiology and Progression of Liver CancerR01CA258386 · NCI · WASHINGTON UNIVERSITY · PI Luis Francisco Zirnberger Batista · 2022 to 2026
$1.8M
Uncovering Novel Regulatory Pathways and Functions of the Telomerase RNA Component in the Hematopoietic SystemR01HL172961 · NHLBI · WASHINGTON UNIVERSITY · PI Luis Francisco Zirnberger Batista · 2025 to 2026
$1.2M
NCI NIH HHS R01 CA258386NHLBI NIH HHS R01 HL172961NHLBI NIH HHS R01 HL174789NIGMS NIH HHS R35 GM150538
6 · The paper itself

Abstract

Telomerase is a large ribonucleoprotein complex responsible for the addition of telomeric DNA repeats to chromosomal ends. Telomerase is composed of core and accessory components that work in coordination to ensure telomere length is maintained during development and in specific cell types. Telomerase activity is tightly regulated and is strongly increased in most tumor cells. On the other hand, loss-of-function mutations either in accessory factors or in core components of the complex impact telomere maintenance and cause a large spectrum of severe phenotypes, typically described as telomere biology disorders. A central element for efficient telomerase function is the proper biogenesis and assembly of the holoenzyme. Here, we discuss our current understanding of these processes and how they modulate telomerase efficiency. We consider how these processes are influenced by the specific subcellular localization of different telomerase components during different stages of the assembly of the holoenzyme. We describe the tremendous progress made in this area over the last decade and how recently discovered aspects of telomerase biogenesis can be exploited clinically, to actively benefit patients suffering from telomere biology disorders.

Indexed as

NeoplasmsTelomeraseAnimalsHumansTelomereTelomere HomeostasisTelomerase

Identifiers

PMID40210447
PMCPMC12354305

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.